Solianis Monitoring AG

Non-invasive glucose monitoring - Solianis Monitoring AG Breakthrough home use study finalized - Board of Directors reinforce

Zurich (ots) - Solianis has just finalized a test series in which patients with diabetes have worn the first configuration of the multisensor system for non-invasive Continuous Glucose Monitoring at home and at work. Results show that the system tracks glucose in these settings and that it is sensitive to hyper- and hypoglycemic glucose excursions. "This is the first study ever performed with any non-invasive glucose sensor in a home use environment. The data show clearly that the technology works and that we are on our way to the final product" says Mario Stark, CEO of Solianis. The company expects to launch its first product in Europe in 2010 after CE approval, targeting this non-invasive device at the insulin dependent diabetes population. Later model variants will address patients with diabetes and impaired glucose tolerance. To move forward with the implementation of the prototype and set up the market introduction, Solianis has strengthened its Board of Directors with two renowned industry experts: Dr. Russ Potts holds a PhD in Biochemistry. He worked at Pfizer on transdermal drug delivery and at Cygnus as Vice President R&D until 2002. Cygnus developed the first FDA-approved, minimally-invasive, continuous glucose monitor "Glucowatch". At Cygnus his responsibilities included FDA technical liaison & fund raising, with strategic as well as technical input. Today he is a consultant for drug delivery and glucose monitoring devices. His role at Solianis will include technical and patent support, recommendations for the approach to the FDA and strategic planning. Dr. Anders Weber holds a Ph.D. in Immunology from the Royal Veterinary and Agricultural University of Copenhagen, and he has performed his post doctorate studies on optical immunosensors at the University of Michigan, Ann Arbor, and the Biotechnology Centre in Pittsburgh. He started his industrial career as Development Engineer at Radiometer A/S in Copenhagen as part of a team developing amperometric glucose and lactate sensors and subsequently headed the advanced Sensors Development Unit. In various capacities, he initiated and managed 12 start-up companies on behalf of Danish Development Finance Corporation and other investors. Solianis Monitoring AG is a medical devices company developing a non-invasive Continuous Glucose Monitor (CGM) for self-monitoring patients with diabetes. Its technology is based on a unique and proprietary multisensor technology for monitoring physiological parameters. It was incorporated in May 2005, and it is funded by private investors and the Pioneer Fund of the Cantonal Bank of Zürich. The Solianis' non-invasive device delivers comparable results to the minimally invasive devices currently approved by the FDA. ots Originaltext: Solianis Monitoring AG Internet: www.presseportal.ch Contact: Mario Stark, CEO Phone: +41/44/306'80'40 Mobile: +41/79/542'88'74 E-Mail:mario.stark@solianis.com Internet: www.solianis.com

Das könnte Sie auch interessieren: